 | Up a level |
2017
Rowe, Steven M., McColley, Susanna A., Rietschel, Ernst, Li, Xiaolei, Bell, Scott C., Konstan, Michael W., Marigowda, Gautham, Waltz, David and Boyle, Michael P. (2017). Lumacaftor/Ivacaftor Treatment of Patients with Cystic Fibrosis Heterozygous for F508del-CFTR. Ann. Am. Thoracic Society, 14 (2). S. 213 - 220. NEW YORK: AMER THORACIC SOC. ISSN 2325-6621
2014
Boyle, Michael P., Bell, Scott C., Konstan, Michael W., McColley, Susanna A., Rowe, Steven M., Rietschel, Ernst, Huang, Xiaohong, Waltz, David, Patel, Naimish R. and Rodman, David (2014). A CFTR corrector (lumacaftor) and a CFTR potentiator (ivacaftor) for treatment of patients with cystic fibrosis who have a phe508del CFTR mutation: a phase 2 randomised controlled trial. Lancet Resp. Med., 2 (7). S. 527 - 539. OXFORD: ELSEVIER SCI LTD. ISSN 2213-2600
Kerem, Elton, Konstan, Michael W., De Boeck, Kris, Accurso, Frank J., Sermet-Gaudelus, Isabelle, Wilschanski, Michael, Elborn, J. Stuart, Melotti, Paola 
ORCID: 0000-0002-5276-1595, Bronsveld, Inez, Fajac, Isabelle ORCID: 0000-0002-1532-1486, Malfroot, Anne, Rosenbluth, Daniel B., Walker, Patricia A., McColley, Susanna A., Knoop, Christiane, Quattrucci, Serena, Rietschel, Ernst, Zeitlin, Pamela L., Barth, Jay, Elfring, Guy L., Welch, Ellen M., Branstrom, Arthur, Spiegel, Robert J., Peltz, Stuart W., Ajayi, Temitayo and Rowe, Steven M.
(2014).
Ataluren for the treatment of nonsense-mutation cystic fibrosis: a randomised, double-blind, placebo-controlled phase 3 trial.
Lancet Resp. Med., 2 (7).
S. 539 - 548.
OXFORD:
ELSEVIER SCI LTD.
ISSN 2213-2600